Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

About this update from Aquestive Therapeutics, Inc.

[{"type":"image","alt":"Aquestive Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aquestive Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/834883b9239a9e55bd9bebae2405df43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hepRKeWnARhKgpkSXI4otQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOA--/https://media.zenfs.com/en/globenewswire.com/834883b9239a9e55bd9bebae2405df43","width":300,"height":77},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hepRKeWnARhKgpkSXI4otQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOA--/https://media.zenfs.com/en/globenewswire.com/834883b9239a9e55bd9bebae2405df43","width":300,"height":77}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United Kingdom","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observed","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Entered into a $150 million debt facility with Oaktree Capital Management, L.P.","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host investor call on May 14, 2026, at 8:00am ET","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":461,"olType":false},{"type":"text","content":"WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic business update.","length":416,"tagName":"p"},{"type":"text","content":"“We made rapid and meaningful progress in the first quarter,” said Daniel Barber, President and Chief Executive Officer of Aquestive. “We successfully completed our Type A meeting with the FDA, aligning on the study designs needed to support resubmission of t...

More updates from Aquestive Therapeutics, Inc.